Ainos
NASDAQ:AIMDWAinos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.
Bone Biologics
NASDAQ:BBLGWBone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
BICO Group AB (publ)
OTCMKTS:CLLKFBICO Group AB (publ) operates as a bioconvergence company in North America, Europe, Asia, and internationally. It operates through three segments: Bioprinting, Biosciences, and Bioautomation. The Bioprinting segment offers products, solutions, and services that enable proliferation of 3D cell culture and 3D printing. The Biosciences segment provides instruments that enable the handling of cells and rare samples, and rapid transfer of liquids and reagents, as well as downstream analysis platforms. The Bioautomation segment offers end-to-end products and services in precision dispensing, advanced sample preparation, multiplex analysis and assay miniaturization, diagnostic and medical device manufacturing for life science and diagnostic industries. It primarily serves medical, pharmaceutical, and cosmetic industries. The company offers its products through sales organizations, as well as through an extensive distributor network. The company was formerly known as Cellink AB (publ) and changed its name to BICO Group AB (publ) in August 2021. BICO Group AB (publ) was incorporated in 2016 and is headquartered in Gothenburg, Sweden.
Cell MedX
OTCMKTS:CMXCCell MedX Corp., a biotech company, discovers, develops, and commercializes therapeutic and non-therapeutic products for patients with diabetes, Parkinson's disease, high blood pressure, neuropathy, and kidney functions. It develops and manufactures eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and eBalance Home System for home use for general wellness and pain management treatment, which are controlled by the eBalance Console that acts as the central controller for three pre-programmed microcurrent algorithms, including wellness, pain management, and dual. The company also develops eBalance Home and eBalance Pro System for temporary relief of shoulder, waist, back, neck, arms, and legs. The company was formerly known as Sports Asylum, Inc. and changed its name to Cell MedX Corp. in September 2014. Cell MedX Corp. was incorporated in 2010 and is headquartered in Carson City, Nevada.